INT88375

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2000
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.12
Pain Relevance 1.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (KNG1) extracellular region (KNG1) plasma membrane (KNG1)
KNG1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 46 100.00 Very High Very High Very High
antagonist 14 100.00 Very High Very High Very High
cytokine 8 100.00 Very High Very High Very High
Kinase C inhibitor 1 89.16 High High
trigeminal ganglion 1 75.00 Quite High
Inflammation 3 71.20 Quite High
cINOD 1 70.76 Quite High
Pain 6 70.52 Quite High
Kinase C 1 60.32 Quite High
Potency 1 52.32 Quite High
Disease Link Frequency Relevance Heat
Sprains And Strains 1 96.92 Very High Very High Very High
Pressure And Volume Under Development 44 93.84 High High
Hereditary Angioedema 126 87.00 High High
Targeted Disruption 3 80.20 Quite High
Recurrence 6 79.28 Quite High
Ganglion Cysts 1 75.00 Quite High
Hypersensitivity 1 74.60 Quite High
INFLAMMATION 5 71.20 Quite High
Pain 3 70.52 Quite High
Body Weight 6 49.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, bradykinin-induced prostaglandin E(2) release was inhibited following treatment with the phospholipase A(2) inhibitor, arachidonyltrifluoromethyl ketone (AACOCF(3)), the nonselective cyclooxygenase inhibitor, piroxicam, the mitogen-activated protein kinase kinase-1 (MEK1) inhibitor, 2'-amino-3'-methoxyflavone (PD98059), and the protein kinase C inhibitor, bisindolylmaleimide XI (Ro320432).
Negative_regulation (inhibited) of Localization (release) of bradykinin-induced associated with bradykinin and kinase c inhibitor
1) Confidence 0.39 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12782182 Disease Relevance 0.22 Pain Relevance 0.80
Structure activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine.
Negative_regulation (inhibition) of Localization (release) of bradykinin associated with antagonist, bradykinin and cytokine
2) Confidence 0.23 Published 2000 Journal Peptides Section Title Doc Link 10822108 Disease Relevance 0.07 Pain Relevance 0.97
C1-inhibitor replacement therapy not only suppresses bradykinin release by inactivation of factor XIIa and kallikrein, but also suppresses activation of the complement system and perhaps of the fibrinolytic and coagulation pathways.
Negative_regulation (suppresses) of Localization (release) of bradykinin associated with bradykinin
3) Confidence 0.15 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.14 Pain Relevance 0.05
It acts as a direct kallikrein inhibitor, blocking its action and preventing the downstream formation of bradykinin.
Negative_regulation (preventing) of Localization (formation) of bradykinin associated with bradykinin
4) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.69 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox